![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/menarini-groups-stemline-inks-500m-biobucks-deal-insilicos-breast-cancer-candidate
https://www.ema.europa.eu/en/documents/overview/orserdu-epar-medicine-overview_en.pdf
https://www.businesswire.com/news/home/20230920907427/en/European-Commission-Approves-Menarini-Group%E2%80%99s-ORSERDU%C2%AE-Elacestrant-for-the-Treatment-of-Patients-with-ER-HER2--Locally-Advanced-or-Metastatic-Breast-Cancer-with-an-Activating-ESR1-Mutation
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761116
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761116
https://www.businesswire.com/news/home/20220811005185/en/Menarini-Group%E2%80%99s-Elacestrant-Granted-Priority-Review-by-the-U.S.-FDA-for-Patients-with-ERHER2--Advanced-or-Metastatic-Breast-Cancer
https://www.businesswire.com/news/home/20200610005445/en/Menarini-Group-Completes-Acquisition-Stemline-Therapeutics